Clinical and laboratory correlates of VxInsight clusters derived from 170 adult AMLs
. | A . | B . | C . | D . | E . | F . | P* . |
|---|---|---|---|---|---|---|---|
| No. patients | 24 | 22 | 31 | 42 | 18 | 33 | — |
| Median age, y (range) | 67 (22-76) | 68 (58-76) | 65 (44-84) | 62 (20-83) | 60 (21-81) | 64 (34-83) | .27 |
| No. with secondary AML (%) | 5 (25) | 7 (32) | 5 (17) | 6 (20) | 2 (22) | 7 (27) | .87 |
| Median pretreatment laboratory values | |||||||
| WBC count, × 109/L | 29 | 6 | 14 | 20 | 33 | 57 | < .001 |
| % PB blasts | 76 | 28 | 38 | 48 | 85 | 11 | < .001 |
| % BM blasts | 82 | 59 | 55 | 71 | 80 | 70 | .004 |
| Platelet count, × 109/L | 36 | 91 | 62 | 42 | 52 | 62 | .002 |
| Hemoglobin level, g/dL | 9.8 | 8.7 | 9.4 | 8.7 | 9.5 | 9.3 | .20 |
| Cytogenetic risk group, no. (%)* | |||||||
| Favorable | 0 (0) | 0 (0) | 1 (3) | 10 (29) | 1 (8) | 0 (0) | < .001 |
| t(8;21) | 0 (0) | 0 (0) | 0 (0) | 8 (24) | 0 (0) | 0 (0) | < .001 |
| Intermediate | 16 (80) | 15 (79) | 19 (66) | 9 (27) | 7 (54) | 17 (71) | < .001 |
| Abnormal | 1 (5) | 7 (37) | 3 (10) | 1 (3) | 1 (8) | 5 (21) | — |
| Normal | 15 (75) | 8 (42) | 6 (55) | 8 (24) | 6 (46) | 12 (50) | .011 |
| Unfavorable, no. (%)† | 4 (20) | 4 (21) | 9 (31) | 15 (44) | 5 (38) | 7 (29) | .41 |
| NPM1 mutation status, no. (%)‡ | |||||||
| NPM1 + (%) | 18/23 (78) | 1/22 (5) | 4/30 (13) | 2/41 (5) | 6/18 (33) | 19/31 (61) | < .001 |
| FLT3 mutation status, no. (%)§ | |||||||
| ITD+ | 8/24 (33) | 3/22 (14) | 6/31 (19) | 13/42 (31) | 5/18 (28) | 11/32 (34) | .467 |
| TKD+ | 5/19 (26) | 0/9 (0) | 2/18 (11) | 3/27 (11) | 1/8 (13) | 2/24 (8) | .404 |
| Both NPM1+ and FLT3-ITD | 7/23 (30) | 1/22 (5) | 2/30 (7) | 2/41 (5) | 3/18 (17) | 10/31 (32) | .003 |
. | A . | B . | C . | D . | E . | F . | P* . |
|---|---|---|---|---|---|---|---|
| No. patients | 24 | 22 | 31 | 42 | 18 | 33 | — |
| Median age, y (range) | 67 (22-76) | 68 (58-76) | 65 (44-84) | 62 (20-83) | 60 (21-81) | 64 (34-83) | .27 |
| No. with secondary AML (%) | 5 (25) | 7 (32) | 5 (17) | 6 (20) | 2 (22) | 7 (27) | .87 |
| Median pretreatment laboratory values | |||||||
| WBC count, × 109/L | 29 | 6 | 14 | 20 | 33 | 57 | < .001 |
| % PB blasts | 76 | 28 | 38 | 48 | 85 | 11 | < .001 |
| % BM blasts | 82 | 59 | 55 | 71 | 80 | 70 | .004 |
| Platelet count, × 109/L | 36 | 91 | 62 | 42 | 52 | 62 | .002 |
| Hemoglobin level, g/dL | 9.8 | 8.7 | 9.4 | 8.7 | 9.5 | 9.3 | .20 |
| Cytogenetic risk group, no. (%)* | |||||||
| Favorable | 0 (0) | 0 (0) | 1 (3) | 10 (29) | 1 (8) | 0 (0) | < .001 |
| t(8;21) | 0 (0) | 0 (0) | 0 (0) | 8 (24) | 0 (0) | 0 (0) | < .001 |
| Intermediate | 16 (80) | 15 (79) | 19 (66) | 9 (27) | 7 (54) | 17 (71) | < .001 |
| Abnormal | 1 (5) | 7 (37) | 3 (10) | 1 (3) | 1 (8) | 5 (21) | — |
| Normal | 15 (75) | 8 (42) | 6 (55) | 8 (24) | 6 (46) | 12 (50) | .011 |
| Unfavorable, no. (%)† | 4 (20) | 4 (21) | 9 (31) | 15 (44) | 5 (38) | 7 (29) | .41 |
| NPM1 mutation status, no. (%)‡ | |||||||
| NPM1 + (%) | 18/23 (78) | 1/22 (5) | 4/30 (13) | 2/41 (5) | 6/18 (33) | 19/31 (61) | < .001 |
| FLT3 mutation status, no. (%)§ | |||||||
| ITD+ | 8/24 (33) | 3/22 (14) | 6/31 (19) | 13/42 (31) | 5/18 (28) | 11/32 (34) | .467 |
| TKD+ | 5/19 (26) | 0/9 (0) | 2/18 (11) | 3/27 (11) | 1/8 (13) | 2/24 (8) | .404 |
| Both NPM1+ and FLT3-ITD | 7/23 (30) | 1/22 (5) | 2/30 (7) | 2/41 (5) | 3/18 (17) | 10/31 (32) | .003 |
P values were determined using χ2 test.
To convert hemoglobin level from grams per deciliter to grams per liter, multiply grams per deciliter by 10.
PB indicates peripheral blood; BM, bone marrow.
n = 139.
11 q23 abnormalities were seen in 9 cases and distributed in clusters A to F as 0, 1, 2, 1, 1, 3, respectively.
n = 165; values given indicate number of patients with the mutation out of number of patients tested.
For ITD, n = 169; for TKD, n = 105. Values given indicate number of patients with the mutation out of number of patients tested.